Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3495
- Registration Number
- NCT00657319
- Locations
- 🇭🇺
Novo Nordisk Investigational Site, Budapest, Hungary
Evaluation of Levemir® for the Treatment of Type 1 and 2 Diabetes
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3637
- Registration Number
- NCT00655044
- Locations
- 🇷🇺
Novo Nordisk Investigational Site, Moscow, Russian Federation
Observational Study of Safety and Tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the Treatment of Type 1 and Type 2 Diabetes Mellitus
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2286
- Registration Number
- NCT00655200
Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 244
- Registration Number
- NCT00634842
- Locations
- 🇵🇷
Novo Nordisk Investigational Site, Trujillo Alto, Puerto Rico
Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-03-03
- Last Posted Date
- 2014-10-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 441
- Registration Number
- NCT00627445
Efficacy and Safety of Biphasic Insulin Aspart 30 With Metformin in Type 2 Diabetes
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2008-02-27
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 140
- Registration Number
- NCT00624364
- Locations
- 🇿🇦
Novo Nordisk Investigational Site, Richards Bay, South Africa
Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 146
- Registration Number
- NCT00623194
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Norfolk, United Kingdom
The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 49
- Registration Number
- NCT00620282
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Rochester, Minnesota, United States
Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 260
- Registration Number
- NCT00619697
- Locations
- 🇸🇮
Novo Nordisk Investigational Site, Maribor, Slovenia
Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 219
- Registration Number
- NCT00617565
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath